1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Both BCMA-Targeting CAR-T Therapies Could Be Approved In 2021

 
• By Mandy Jackson

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

Multiple Myeloma Awareness: Bone marrow aspirate cytology of multiple myeloma, a type of bone marrow cancer of malignant plasma cells, associated with bone pain, bone fractures and anemia.
BCMA-targeting CAR-T therapies show durable responses in multiple myeloma • Source: Shutterstock

Longer-term results for Janssen Pharmaceutical Cos. and Legend Biotech Corp.’s ciltacabtagene autoleucel (cilta-cel) show that multiple myeloma patients treated with the B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapy maintained responses over time. But while the overall response and complete response rates reported on 5 December at the virtual American Society of Hematology (ASH) annual meeting are higher than those observed with idecabtagene vicleucel (ide-cel) from Bristol Myers Squibb Company and bluebird bio, longer-term data for ide-cel show lower incidences of cytokine release syndrome (CRS) and severe neurotoxicity. 

The BMS/bluebird asset also has the benefit of time, since a biologic license application (BLA) for ide-cel already is under...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.